These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 24121487)
1. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Kinde I; Munari E; Faraj SF; Hruban RH; Schoenberg M; Bivalacqua T; Allaf M; Springer S; Wang Y; Diaz LA; Kinzler KW; Vogelstein B; Papadopoulos N; Netto GJ Cancer Res; 2013 Dec; 73(24):7162-7. PubMed ID: 24121487 [TBL] [Abstract][Full Text] [Related]
2. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021 [TBL] [Abstract][Full Text] [Related]
3. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential. Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225 [TBL] [Abstract][Full Text] [Related]
4. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine. Descotes F; Kara N; Decaussin-Petrucci M; Piaton E; Geiguer F; Rodriguez-Lafrasse C; Terrier JE; Lopez J; Ruffion A Br J Cancer; 2017 Aug; 117(4):583-587. PubMed ID: 28683471 [TBL] [Abstract][Full Text] [Related]
5. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications. Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924 [TBL] [Abstract][Full Text] [Related]
6. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer. Roggisch J; Ecke T; Koch S Urol Oncol; 2020 Mar; 38(3):77.e17-77.e25. PubMed ID: 31521529 [TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer. Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201 [TBL] [Abstract][Full Text] [Related]
8. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer. Hayashi Y; Fujita K; Nojima S; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Morii E; Nonomura N Mol Oncol; 2020 Oct; 14(10):2375-2383. PubMed ID: 32533903 [TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484 [TBL] [Abstract][Full Text] [Related]
12. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma. Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872 [TBL] [Abstract][Full Text] [Related]
13. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder. Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299 [TBL] [Abstract][Full Text] [Related]
14. TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region. Pakmanesh H; Anvari O; Forey N; Weiderpass E; Malekpourafshar R; Iranpour M; Shahesmaeili A; Ahmadi N; Bazrafshan A; Zendehdel K; Kannengiesser C; Ba I; McKay J; Zvereva M; Hosen MI; Sheikh M; Calvez-Kelm FL Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430798 [TBL] [Abstract][Full Text] [Related]
15. Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma. Eich ML; Rodriguez Pena MDC; Springer SU; Taheri D; Tregnago AC; Salles DC; Bezerra SM; Cunha IW; Fujita K; Ertoy D; Bivalacqua TJ; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Netto GJ Mod Pathol; 2019 Oct; 32(10):1544-1550. PubMed ID: 31028363 [TBL] [Abstract][Full Text] [Related]
16. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change. Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899 [TBL] [Abstract][Full Text] [Related]
17. Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications. Cheng L; Lopez-Beltran A; Wang M; Montironi R; Kaimakliotis HZ; Zhang S Mod Pathol; 2021 Jul; 34(7):1384-1391. PubMed ID: 33674765 [TBL] [Abstract][Full Text] [Related]
18. Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study. Hosen MI; Sheikh M; Zvereva M; Scelo G; Forey N; Durand G; Voegele C; Poustchi H; Khoshnia M; Roshandel G; Sotoudeh M; Nikmanesh A; Etemadi A; Avogbe PH; Chopard P; Delhomme TM; Foll M; Manel A; Vian E; Weiderpass E; Kamangar F; Boffetta P; Pharaoh PD; Dawsey SM; Abnet CC; Brennan P; McKay J; Malekzadeh R; Calvez-Kelm FL EBioMedicine; 2020 Mar; 53():102643. PubMed ID: 32081602 [TBL] [Abstract][Full Text] [Related]
19. Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. Cowan ML; Springer S; Nguyen D; Taheri D; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; Del Carmen Rodriguez Pena M; VandenBussche CJ; Olson MT; Cunha I; Fujita K; Ertoy D; Kinzler K; Bivalacqua T; Papadopoulos N; Vogelstein B; Netto GJ Hum Pathol; 2016 Jul; 53():8-13. PubMed ID: 26980028 [TBL] [Abstract][Full Text] [Related]
20. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis. Günes C; Wezel F; Southgate J; Bolenz C Nat Rev Urol; 2018 Jun; 15(6):386-393. PubMed ID: 29599449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]